Company
Headquarters: South San Francisco, CA, United States
Employees: 55
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
$908.7 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $161.9 M |
| EBITDA | $-189,212,000 |
| Gross Profit TTM | $153.8 M |
| Profit Margin | -42.66% |
| Operating Margin | -133.50% |
| Quarterly Revenue Growth | 5.32% |
Day One Biopharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: DAWN wb_incandescent